CD Biosynsis offers specialized PEGylation services for antibody fragments, including Fab (Fragment antigen-binding) and scFv (single-chain variable fragments). While these smaller formats offer superior tissue penetration and reduced immunogenicity compared to full-length IgGs, they are hindered by extremely rapid renal clearance, often possessing circulatory half-lives of only a few hours. Our platform utilizes precision PEGylation to increase the hydrodynamic volume of these fragments beyond the renal filtration threshold, transforming rapidly cleared molecules into long-acting therapeutic candidates.
Our approach is designed to preserve the high affinity and specificity of your antibody fragments. By utilizing site-specific conjugation strategies, we ensure that the PEG polymer is attached at a location distal to the Complementarity-Determining Regions (CDRs). This prevents steric hindrance of the antigen-binding site, ensuring that the half-life extension does not come at the cost of therapeutic potency. From scFv stabilization to Fab functionalization, we provide end-to-end support including structural modeling, customized linker synthesis, and high-resolution characterization.
Get a QuoteAntibody fragments like scFvs (approx. 25 kDa) and Fabs (approx. 55 kDa) fall well below the renal filtration threshold of approximately 60 to 70 kDa. PEGylation is the most effective clinical strategy to increase their effective size without the complexity of Fc-fusion. By attaching a 20 kDa or 40 kDa PEG chain, the hydrodynamic radius is significantly expanded, effectively "shielding" the fragment from rapid kidney excretion and proteolytic degradation in the serum.
We emphasize site-specific modification to maintain the orientation of the fragment. For scFvs, we often utilize C-terminal cysteine engineering or N-terminal reductive alkylation to ensure the variable domains remain fully accessible to the target antigen. For Fab fragments, we can target the interchain disulfide bonds or engineer specific amino acid handles. This precision ensures a homogeneous drug product with a defined drug-to-polymer ratio, facilitating a smoother path through regulatory characterization and clinical trials.
C-terminal Thio-PEG
Engineering a C-terminal cysteine to allow for high-efficiency maleimide-thiol coupling, keeping the binding paratope free.
Linker Engineering
Optimizing the (Gly4Ser)3 linker length between VH and VL domains to accommodate the PEG cloud without inducing misfolding.
Disulfide Re-bridging
Utilizing bis-sulfone or maleimide reagents to conjugate PEG while simultaneously re-linking the heavy and light chains.
Enzymatic Tagging
Using Sortase A or Transglutaminase to attach PEG to specific peptide motifs integrated into the Fab constant regions.
Branched PEGs
Utilizing Y-shaped branched polymers to provide a denser "umbrella" shield for better protease resistance in small fragments.
Multi-arm PEGs
Construction of multi-valent fragment systems (e.g., Di-Fab or Di-scFv) to increase avidity and target binding strength.
Our systematic workflow ensures high-fidelity conjugation and definitive validation of fragment bioactivity.
1. Computational Design
2. Site-Specific Build
3. Purification
4. Affinity Validation
Modeling the scFv/Fab surface to identify residues distal to CDRs. Selection of the optimal PEG molecular weight to reach the desired pharmacokinetic window.
Expression of modified fragments with engineered handles (Cys, N-term, or enzymatic tags). Implementation of site-specific conjugation under mild physiological conditions.
Confirming 1:1 stoichiometry via MALDI-TOF or ESI-MS. Verifying antigen-binding kinetics via SPR (Biacore) to ensure affinity is preserved.
CDR Protection
Our site-specific targeting ensures that the PEG polymer does not interfere with the antigen-binding loops, preserving therapeutic efficacy.
Homogeneous DAR
Absolute control over the degree of PEGylation (typically 1:1) to ensure a uniform molecular entity for clinical and regulatory consistency.
Superior PK Extension
Extending scFv/Fab half-life from hours to days, reducing dosing frequency while maintaining the fragment advantage in tissue penetration.
Fragment Stability
The PEG shell helps prevent the aggregation and physical instability often associated with small, high-concentration scFv formulations.
1. Will PEGylation significantly decrease the binding affinity of my scFv?
If performed randomly, yes. However, our site-specific approach targets sites distal to the CDRs. While a small drop in association rate (kon) may occur due to local viscosity, the overall affinity is usually well-preserved.
2. What PEG size is recommended for a 25 kDa scFv?
To bypass renal filtration, we typically recommend a PEG of at least 20 kDa or 40 kDa. A 40 kDa branched PEG is often the best choice for maximizing half-life in small formats.
3. Can you perform PEGylation on bispecific fragments?
Yes. Bispecific formats like BiTEs or Tandem scFvs are highly prone to rapid clearance. We can optimize PEG placement to ensure both binding arms remain functional.
4. How do you handle the potential for scFv aggregation during conjugation?
We utilize mild physiological buffers and optimized reaction temperatures. Often, the addition of the PEG chain itself significantly improves the solubility and stability of the fragment.
5. Is the PEG attachment to the Fab fragment stable?
We utilize stable thioether or amide bonds. For Fab fragments, our disulfide re-bridging chemistry ensures the PEG is attached while maintaining the covalent link between light and heavy chains.
6. How do you confirm site-specificity?
We use LC-MS/MS peptide mapping. We digest the conjugate and identify the specific peptide fragment carrying the PEG-modified residue, confirming it is not in the CDR region.
7. Can PEGylation help with the immunogenicity of fragments?
Yes. Antibody fragments can sometimes expose neo-epitopes. The PEG "cloud" masks these surface features, reducing recognition by the host immune system.
8. What is the typical turnaround time for a purified PEG-scFv?
From receipt of the fragment to delivery of the characterized, mono-PEGylated product, the typical timeframe is 8 to 12 weeks.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.